Sponsored Links 
Zacks Analyst Blog Highlights: Osiris Therapeutics, Inc., Genzyme Corp., Barclays PLC, Intersil Corporation and Isis Pharmaceuticals.
Print
ShareFor Immediate Release
Chicago, IL – May 11, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Osiris Therapeutics, Inc. (OSIR), Genzyme Corp. (GENZ), Barclays PLC (BCS), Intersil Corporation (ISIL) and Isis Pharmaceuticals (ISIS).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.
Here are highlights from Friday's Analyst Blog:
Optimistic on Osiris
Osiris Therapeutics, Inc. (OSIR) reported financial results for the first quarter 2009 on May 7, 2009. Total revenues in the quarter were $12.7 million, up from $0.4 million for the same period for 2008, and slightly above our forecasts of $11.8 million.
Revenues include the recognition of $10.0 million in amortized license fees from Genzyme Corp. (GENZ) and $2.6 million related to the contract with the U.S. Department of Defense. The company reported net income of $14.8 million, or $0.45 per share for the quarter. This figure is comprised of losses from continuing operations of $7.9 million, or $0.24 per share, and income from discontinued operations of $22.7 million, or $0.69 per share.
Barclays Boosted by Lehman Ops
Today, Barclays PLC (BCS, or Barclays) posted a 15% year-over-year increase in pretax profits to £1.4 billion, driven by a 361% gain in pretax earnings to £907 million at Barclays Capital, stemming from the acquisition and integration of Lehman's North American operations. While net income attributable to shareholders rose 12%, diluted earnings per share dropped 33% due to dilution caused from the sale of additional shares last year.
Net revenues increased 42% year over year due to the Lehman acquisition and strong growth at the international businesses in Global Retail and Commercial Banking on growth in assets. However, profits at all of Barclays' retail and commercial banking operations were hit by a sharp deterioration in credit quality and higher loan impairment charges, particularly in the UK, Spain, and India. Total impairment charges rose 79% year over year to £2.3 billion, including £1.1 billion at Barclays Capital, which was up 45% year over year and included credit market write-downs of £754 million.
Intersil Corporation Looks Ahead
Intersil Corporation (ISIL) is an OEM of analog and mixed signal semiconductor ICs. Management expressed confidence that the bottom is behind it, and judging from the increasing order rates and growing backlog, we are inclined to agree.
The High Performance Analog market is a key reason we are bullish on the shares.
Isis Our Top Mid-Cap Biotech Pick
We are keeping our Buy rating and $22 price target on Isis Pharmaceuticals (ISIS). We are big fans of antisense technology and believe that the number of potential therapeutic applications is enormous. Antisense drugs may have significant potential to treat a number of diseases where small molecule and biologic compounds have failed.
Although still early-stage, antisense technology as a platform for developing drugs reminds us greatly of the promise of biologic drugs over a decade ago. Potential mechanisms such as siRNA, RNAi, alternate splicing and micro RNA have the potential to change how we treat disease in the years to come.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
Loading Stories...
More Zacks Resources
More Zacks Links
| Market Summary | Feb 10, 2012 08:59 am ET |
-102.47